Sanofi taps Adimab for antibody R&D

Sanofi ($SNY) inked a deal with the antibody discovery experts at Adimab, partnering up to generate a fleet of potential medicines. Neither side is disclosing financial details, but the collaboration will see Adimab use its proprietary engine to identify monoclonal and bispecific antibodies against some unnamed targets, handing Sanofi the rights to research and license each project. In exchange, Adimab gets an up-front payment, research fees and further compensation tied to technical milestones. And, if Sanofi pulls the trigger on any of the candidates, the biotech is in line for license fees, clinical milestone payments and royalties on sales. Sanofi joins an impressive list of drugmakers allured by Adimab's expertise, including Merck ($MRK), Roche ($RHHBY), Novartis ($NVS), Eli Lilly ($LLY) and GlaxoSmithKline ($GSK). More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.